drugset / Trial / NCT02463305

Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)

NCT02463305

Phase 0 Withdrawn University of Colorado, Denver
RandomizedParallel-groupTriple-blindTreatment

Summary

This study plans to learn more about the effects that creatine monohydrate has on disease activity in ulcerative colitis. Creatine is a substance that is naturally produced by the body and is found in foods, such as meat and fish. Creatine helps to provide energy to some body tissues, such as the colon. In the colon, this energy allows cells to form a tight barrier between molecules in digested food and bacteria and the body's infection-fighting cells within the colon underneath this barrier. If the barrier becomes "leaky" molecules may pass through and lead to inflammation. This "leakiness" may contribute to the colon inflammation seen in ulcerative colitis.

Timeline

Start
2022-08
Primary completion
2023-03-01
Completion
2023-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Creatine Other / unclassified 7 g Oral

Indications